- Home
- ESPR
as 03-13-2025 4:00pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 305.0M | IPO Year: | 2013 |
| Target Price: | $6.36 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.47 - $3.94 | Next Earning Date: | 03-04-2025 |
| Revenue: | $332,314,000 | Revenue Growth: | 185.66% |
| Revenue Growth (this year): | 5.51% | Revenue Growth (next year): | 1.42% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Warren Eric | ESPR | Chief Commercial Officer | Feb 19 '25 | Sell | $1.87 | 239 | $446.45 | 159,759 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Feb 19 '25 | Sell | $1.86 | 11 | $20.46 | 240,671 | |
| Warren Eric | ESPR | Chief Commercial Officer | Jan 17 '25 | Sell | $2.26 | 123 | $277.98 | 159,759 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Jan 17 '25 | Sell | $2.27 | 9 | $20.39 | 240,671 | |
| Warren Eric | ESPR | Chief Commercial Officer | Dec 17 '24 | Sell | $2.43 | 2,234 | $5,426.39 | 159,759 | |
| Koenig Sheldon L. | ESPR | President and CEO | Dec 17 '24 | Sell | $2.47 | 12,447 | $30,694.30 | 739,819 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Dec 17 '24 | Sell | $2.42 | 3,245 | $7,865.88 | 240,671 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Thomson Reuters StreetEvents
9 days ago
Q4 2024 Esperion Therapeutics Inc Earnings Call
Zacks
10 days ago
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
Associated Press Finance
10 days ago
Esperion Therapeutics: Q4 Earnings Snapshot
GlobeNewswire
10 days ago
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
11 days ago
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
Insider Monkey
13 days ago
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
Zacks
16 days ago
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.